COLOGNE, Germany and NEUMÜNSTER, Germany, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced that its ...
~ Late-breaking presentation demonstrates that a repeat dose of NDS1C epinephrine nasal spray within five minutes safely increases epinephrine absorption by approximately 50 percent compared with a single dose ~ ~ Additionally, new ...
--VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU-- SHANGHAI , Feb. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the ...
SHANGHAI , Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Orphan Drug Designation (ODD) to 9MW3011 (R&D code in the US: ...
SHANGHAI , Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of B7-H3 targeting ADC (R&D code: 7MW3711) for advanced ...
ROCKVILLIE, MD. and SUZHOU, China , Feb. 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the ...
SHANGHAI , Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs ...
- New Company to support New Drug Application- HAYWARD, Calif. , Feb. 15, 2024 /PRNewswire/ -- HealthBio AI , a recently launched precision immunology company advancing new science for neglected immune-mediated diseases, today ...
- Fast Track designation indicates CBL-514's potential in filling the unmet medical need of Dercum's disease. - CBL-514 is the first drug to receive Fast Track designation for Dercum's disease treatment. - CBL-514 Phase 2 study in ...
KRAKOW , Poland , Feb. 14, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today ...
Providing rotavirus vaccine to infants in neonatal intensive care units (NICUs) is safe and does not lead to disease outbreaks ( ). Rotaviruses are majorly responsible for diarrheal disease among infants and young children. The vaccine, which ...
Dapagliflozin, a medication prescribed for managing Type 2 diabetes , has demonstrated additional benefits in heart failure conditions. This drug lowers the likelihood of hospitalization due to heart failure and mortality in ...
The efficacy of mRNA vaccine technology demonstrated during the COVID-19 pandemic provides optimism for its utilization in mitigating preventable illnesses across various disease domains ( ). ...
An intradermal monkeypox (Mpox) vaccination regimen with reduced dosage proved safe and elicited an antibody response comparable to the standard regimen at six weeks (two weeks post-second dose) ( ). ...
The World Health Organization (WHO) granted prequalification to a novel oral cholera vaccine on April 12. The Euvichol-S oral vaccine, which is inactivated, demonstrates comparable effectiveness to the current vaccines, ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers